# Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

> **NCT05162274** · PHASE1 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 38 (actual)

## Conditions studied

- Healthy Adult Volunteers

## Interventions

- **DRUG:** Lazertinib(G001)
- **DRUG:** Lazertinib(G002)

## Key facts

- **NCT ID:** NCT05162274
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162274, "Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05162274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*